Kazuhiro Takahashi, PURMX Therapeutics – Novel MicroRNA-based Medicine for Oncology | LSI Asia '25

PURMX Therapeutics is developing novel nucleic acid medicines using proprietary small RNA-based technologies designed to modulate multiple gene targets. The company’s lead candidate, MIRX002, is a microRNA-based therapy for malignant pleural mesothelioma, currently being evaluated in investigator-initiated clinical trials at Hiroshima University Hospital. PURMX has also initiated a sponsor-led trial in Japan for head and neck squamous cell carcinoma (HNSCC).
Join Our Next Event
Partner with the leaders
shaping the future of
Medtech at LSI USA ‘26
March 16th - 20th, 2026
Waldorf Astoria, Monarch Beach